Comparative studies of infectivity, immunogenicity and cross-protective efficacy of live attenuated influenza vaccines containing nucleoprotein from cold-adapted or wild-type influenza virus in a mouse model
NP-specific CTL response to 6:2 LAIV might be outdated; Inclusion of wild-type NP (5:3 genotype) improves cross-protection of LAIV; Wild-type NP has little or no impact on biological features of LAIV. We recommend generating 5:3 reassortants for PR8-based IIV to improve CTL response.